SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Keywords:
Lung neoplasms
Tumor microenvironment
Lymphocytes
Tumor-infiltrating
Drug evaluation
Preclinical
Note:
This is an open access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license
Citation:
Redín-Cabodevilla, M. (María Esther); Garmendia-Iturbe, I. (Irati); Lozano-Moreda, T. (Teresa); et al. "SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation". Journal for Immunotherapy of Cancer. 9 (3), 2021, e001496
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.